Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Treatment of Diabetic Retinopathy for Subjects Who Completed the 2-Year PANORAMA Trial

PHASE4CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

June 1, 2021

Primary Completion Date

July 31, 2024

Study Completion Date

July 31, 2024

Conditions
Diabetic Retinopathy
Interventions
DRUG

Aflibercept Injection

Intravitreal 2mg aflibercept injection

Trial Locations (14)

21740

Cumberland Valley Retina Consultants, P.C., Hagerstown

29169

Palmetto Retina Center, West Columbia

29501

Palmetto Retina Center, LLC - Florence, Florence

30060

Marietta Eye Clinic, Marietta

32806

Central Florida Retina Center, Orlando

33880

Center for Retina and Macular Disease, Winter Haven

38138

Charles Retina Institute, Germantown

47150

John Kenyon American Eye Institute, New Albany

73104

Dean McGee Eye Institute, Oklahoma City

76087

Strategic Clinical Research Group, LLC, Willow Park

77401

Retina Consultants of Texas, Bellaire

78550

Valley Retina Institute, Harlingen

90211

Retina Vitreous Associates Medical Group, Beverly Hills

00613

Emanuelli Research and Development Center, LLC, Arecibo

All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

collaborator

Clinical Trials Resource Group, LLC

UNKNOWN

lead

Greater Houston Retina Research

OTHER